Recent business developments include ending a licensing agreement with Teleost and partnering with AAVnerGene to accelerate gene therapy development. The company also presented at Biotech Showcase 2025 on innovative therapies for neurodegenerative diseases.

• Greenland Mines ended its licensing agreement with Teleost as of April 1, 2026 [N1].
• The company partnered with AAVnerGene in July 2025 to accelerate cost-effective gene therapy development [N2].
• Greenland Mines presented at Biotech Showcase 2025 on innovative therapies for neurodegenerative diseases in January 2025 [N5].
• Discussions about company stock activity and market interest were noted in mid-2025 [N3][N4].

The company's gene therapy platform targeting the Klotho protein is supported by promising pre-clinical data demonstrating neuroprotective and anti-aging effects in animal models. The exclusive licensing agreements and patents provide a foundation for potential novel treatments for Alzheimer's, ALS, and other age-related diseases. The acquisition of generic and biosimilar drug portfolios offers near-term commercial opportunities. Expansion into critical minerals mining diversifies operations. Strategic partnerships, such as with AAVnerGene, aim to accelerate gene therapy development, potentially enhancing technological capabilities and market positioning.

Greenland Mines faces significant risks inherent in early-stage gene therapy development, including regulatory hurdles, clinical trial uncertainties, and high R&D costs. The company reported a net loss and limited revenue visibility, indicating ongoing funding needs. The recent expansion into mining represents a strategic shift that may dilute focus and resources. The competitive landscape in neurodegenerative disease therapies is intense, and the success of proprietary Klotho-based therapies remains unproven in humans. Dependence on licensing agreements and collaborations introduces execution risks.

Greenland Mines' moat is based on its proprietary gene therapy platform targeting the Klotho protein, supported by exclusive worldwide licensing agreements and patents. The platform addresses significant unmet medical needs in neurodegenerative diseases, leveraging novel scientific discoveries and pre-clinical validation. The company's acquisition of market-approved generic and biosimilar drugs provides a complementary revenue base. The integration of gene therapy with diagnostic assay development enhances potential differentiation. However, the gene therapy field is competitive and high-risk, with regulatory and clinical development challenges.

• Clinical and Regulatory Risk: The gene therapy candidates are in pre-clinical stages, and successful clinical development and regulatory approval are uncertain and may require significant time and investment.
• Financial Risk: The company reported net losses and relies on available cash and financing to fund operations, which may impact its ability to sustain R&D and expansion activities.
• Strategic Risk: The acquisition of Greenland Mines Corp. and entry into critical minerals mining may divert management focus and resources from core biopharmaceutical development.
• Competitive Risk: The neurodegenerative disease treatment market is highly competitive with multiple players developing alternative therapies, which may affect market adoption of Greenland Mines' products.

• Greenland Mines Ltd, formerly Klotho Neurosciences, develops medicines for chronic diseases including cancer, cardiovascular, and neurodegenerative disorders.
• The company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform for cancer treatment, and a proprietary gene therapy platform targeting neurodegenerative diseases using the therapeutic protein Klotho.
• In September 2022, Greenland Mines acquired five market-approved anti-cancer drugs in Germany, including drugs used in FOLFOX and FOLFIRI regimens for metastatic colorectal, gastric, and lung cancers.
• In March 2026, Greenland Mines Corp. was acquired, expanding operations into critical and precious minerals development and mining.
• The company trades on Nasdaq under symbols GRML and GRMLW.
• The gene therapy platform focuses on the Klotho gene and its secreted isoform s-KL, which is being developed for neurodegenerative diseases such as Alzheimer's and ALS.
• The Klotho gene therapy candidates are in pre-clinical stages, with plans to seek market approval in multiple countries including the US, Canada, Europe, and China.
• Scientific research supports the neuroprotective and anti-aging potential of Klotho protein, with animal studies showing cognitive improvements and mitigation of neurodegenerative disease markers.
• Greenland Mines is developing assays to measure Klotho protein isoforms to support gene therapy development and potential diagnostics.
• The company has two lead gene therapy candidates: KLTO-101 for Alzheimer's disease and KLTO-202 for ALS.
• Financial snapshot as of 2026-06-30 shows cash and equivalents of $9.3 million, current assets of $12.2 million, current liabilities of $1.2 million, a current ratio of 10.09, and a cash ratio of 7.69, indicating strong liquidity.
• Net income for the period ending 2026-06-30 was a loss of $3.685 million, with basic and diluted EPS of -$0.03 per share.
• Recent business news includes ending a licensing agreement with Teleost and partnering with AAVnerGene to accelerate gene therapy development.
• The company presented at Biotech Showcase 2025 on innovative therapies for neurodegenerative diseases.